Inhibikase stock sinks on FDA's unexpected clinical hold for lead asset's Parkinson's trial

Inhibikase Therapeutics has been left stumped and its stock bruised after the FDA unexpectedly placed a clinical hold on its midstage Parkinson’s disease drug.

The therapy, an Abelson tyrosine kinase inhibitor called IkT-148009, was undergoing a phase 2 trial for Parkinson’s.